Health Care • Biotechnology: Pharmaceutical Preparations
$28.76 ▼ -0.01
(-0.04%)
MKT CAP: $1.87B • VOL: 373.0K
52W L $14 52W H $45
ZBIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $10.0M | $5.0M | $50.0M |
| YoY Revenue Growth % | +100.0% | -90.0% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$383.1M | -$163.9M | -$37.1M |
| Operating Margin % | -80.0% | -80.0% | -74.3% |
| Net Income (GAAP) | -$377.7M | -$157.0M | -$37.1M |
| EBITDA (Normalized) | -$383.0M | -$163.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$172.3M | -$119.7M | -$30.5M |
| Capital Expenditures (CapEx) | $18.0K | $131.0K | — |
| Free Cash Flow (FCF) | -$172.4M | -$119.8M | -$30.5M |
| FCF Margin % | -80.0% | -80.0% | -61.1% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $110.6M | $319.7M | — |
| Total Debt (Short + Long Term) | $78.6M | — | — |
| Total Stockholders' Equity | $242.1M | $312.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ZBIO.